Introduction
============

Ameloblastoma is a slow-growing but locally infiltrative odontogenic neoplasm of the jaws [@b1],[@b2], whose aetiology and pathogenesis are not understood. Due to their often complex growth pattern, most ameloblastomas are treated by surgical resection, often resulting in facial deformity and significant morbidity. More conservative approaches tend to result in recurrence and further surgery. Targeted therapy could potentially eliminate the need for extensive and/or repeated surgery.

ERBB receptors are a receptor tyrosine kinase subfamily that includes the epidermal growth factor receptor (EGFR), ERBB2, ERBB3 and ERBB4. ERBB receptors are indispensable for development and frequently dysregulated in human malignancies [@b3]. EGFR and its ligands, EGF and transforming growth factor-*α* (TGFA) are expressed in the odontogenic epithelium of normal developing teeth [@b4], and strong EGFR expression has also been detected in ameloblastoma [@b4]--[@b6].

Here, we analysed the expression of all ERBB receptors in clinical ameloblastoma samples, using real-time RT--PCR. We also studied the role of ERBB signalling and assessed the feasibility of ERBB-targeted therapeutics in novel primary ameloblastoma cell lines. Furthermore, we report a high frequency of oncogenic BRAF V600E mutations in clinical ameloblastoma samples and demonstrate that BRAF V600E mutation was associated with resistance to EGFR-targeted drugs in primary ameloblastoma cells.

Materials and methods
=====================

Patients and tissue specimens
-----------------------------

Fresh frozen tumour samples from 24 conventional intra-osseous ameloblastomas (Table [1](#tbl1){ref-type="table"}), eight sporadic keratocystic odontogenic tumours (KCOT) and six samples of normal oral mucosa (see supplementary material, Table S1) were included in the study. Two ameloblastoma samples were from the primary and recurrent tumours of the same patient (samples 17 and 18; Table [1](#tbl1){ref-type="table"}). Ethics Committee approvals (1--11 March 2007, 0/H0703/054 and CPP53-10) and the patients\' written informed consents were obtained in accordance with the Helsinki Declaration.

###### 

Clinical information and BRAF mutation status of the ameloblastoma patients; cases arranged as in Figure [1](#fig01){ref-type="fig"}

  Sampleno.   Age   Sex   Ethnicity             Location                   Primary/recurrent   Histology                   Notes                                                         BRAF status   BRAF V600EIHC
  ----------- ----- ----- --------------------- -------------------------- ------------------- --------------------------- ------------------------------------------------------------- ------------- --------------------------------------
  1           66    M     Caucasian             Right mandible             Primary             S/MC follicular             Enucleated                                                    V600E         Pos
  2           70    F     Asian                 Left mandible              Primary             S/MC follicular             Enucleated                                                    V600E         Pos
  3           61    M     Caucasian             Right posterior mandible   Primary             S/MC plexiform              Resected                                                      WT            Neg
  4           27    F     Black-Somali          Middle mandible            Primary             S/MC follicular             Enucleated                                                    V600E         Pos
  5           24    F     Black                 Right mandible             Primary             S/MC plexiform              Enucleated                                                    V600E         Pos
  6           50    F     Black                 Left mandible              Recurrence          Plexiform                   Resected, tumour sample decalcified in formic acid            V600E         Neg[\*](#tf1-1){ref-type="table-fn"}
  7           36    M     Afro-Caribbean        Left mandible              Residual            S/MC follicular             Enucleated                                                    WT            Neg
  8           47    M     Caucasian             Mandible                   Primary             S/MC follicular             Resected                                                      V600E         Pos
  9           32    M     North African         Right posterior mandible   1st recurrence      S/MC plexiform              Primary tumour at age 27; enucleated                          WT            NA
  10          46    M     African               Middle anterior mandible   3rd recurrence      S/MC follicular             Primary tumour at age 25; radical resection                   V600E         NA
  11          14    M     Black-North African   Left posterior mandible    Primary             S/MC plexiform              Left angle and ramus                                          V600E         Pos
  12          34    F     Caucasian             Left posterior mandible    1st recurrence      S/MC follicular             Resected                                                      V600E         Pos
  13          84    M     Caucasian             Right mandible             Primary             S/MC follicular             Resected                                                      WT            Neg
  14          18    F     Caucasian             Left anterior mandible     Primary             S/MC follicular             Enucleated                                                    V600E         NA
  15          16    M     Caucasian             Mandible                   Primary             S/MC plexiform              Enucleated                                                    V600E         Pos
  16          61    F     NA                    Right mandible             Primary             S/MC plexiform/follicular   Enucleated                                                    WT            Neg
  17          69    M     Caucasian             Left posterior mandible    Primary             S/MC plexiform              Primary tumour for sample 18; enucleated                      WT            Neg
  18          77    M     Caucasian             Left posterior mandible    1st recurrence      S/MC plexiform              Recurred after 8 years, primary tumour sample 17              WT            Neg
  19          69    M     Caucasian             Right posterior mandible   Primary             S/MC plexiform              Patient died after operation                                  WT            Neg
  20          43    M     Caucasian             Right body mandible        Primary             S/MC follicular             Enucleated                                                    V600E         Pos
  21          44    F     Black-African         Right posterior mandible   Primary             S/MC plexiform              No recurrence after 5 years                                   V600E         Pos
  22          33    M     African               Middle anterior mandible   3rd recurrence      S/MC follicular             Primary tumour at age 20; enucleated                          V600E         Pos
  23          46    F     Afro-Caribbean        Left body mandible         1st recurrence      S/MC plexiform              Primary tumour at age 34; resected                            V600E         NA
  24          31    M     Black-African         Left posterior mandible    Primary             S/MC follicular             Recurred after 5 years, no real-time RT--PCR data available   WT            Neg

Decalcification of ameloblastoma tumour samples using formic acid may hinder the BRAF V600E immunohistochemistry.

S/MC, solid/multicystic; WT, wild-type; NA, data/sample not available; IHC, immunohistochemistry.

Real-time RT--PCR
-----------------

RNA isolation and real-time RT--PCR (TaqMan, Applied Biosystems) analyses were carried out as previously described [@b7],[@b8]. The amount of tumour tissue in the samples was \>90%. Primer and probe sequences have been described previously [@b8] or are described in Table S2 (see supplementary material). One ameloblastoma sample (patient sample 24) was not included in the analysis, due to insufficient RNA concentration.

Establishment of primary ameloblastoma cells and ameloblastoma fibroblasts
--------------------------------------------------------------------------

Fresh samples from ameloblastoma tumours (AB10, patient 3; ABSV, patient 12; see Table [1](#tbl1){ref-type="table"}) were cut into small pieces (approximately 1 × 1 mm) and placed in T25 cell culture flasks with 1 ml CnT-24 medium (CELLnTEC), supplemented with Pen/Strep/Amphotericin B Solution (CELLnTEC). Outgrowing ameloblastoma cells were harvested at confluence and maintained in the CnT-24 medium. Primary ameloblastoma fibroblast (AF) cultures were established from an ameloblastoma sample (tumour not analysed in this study) as above, using Dulbecco\'s modified Eagle\'s medium (DMEM; Invitrogen) supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin and 50 µg/ml streptomycin as the culture medium.

Antibodies and inhibitors
-------------------------

The EGFR antibodies cetuximab and panitumumab, as well as the ERBB2 antibody trastuzumab, were purchased from Turku University Hospital pharmacy. The EGFR tyrosine kinase inhibitors gefitinib and erlotinib were purchased from Santa Cruz Biotechnology. EGFR/ERBB4 inhibitor AG1478, PI3K inhibitor LY294002 and MEK inhibitor PD98059 were purchased from Calbiochem (Merck Millipore).

MTT cell viability assay
------------------------

AB10 and ABSV cells were plated onto 96-well plates in triplicate, at a density of 3500 cells/well, in CnT-24 Oral Epithelium Medium, with or without inhibitors. After 72 h, the number of viable cells was estimated using the MTT assay (CellTiter 96 non-radioactive cell proliferation assay; Promega) according to the manufacturer\'s guidelines.

Western blotting
----------------

Cells growing on six-well plates were treated overnight with EGFR, ERBB2, AKT or MEK inhibitors or for 10 min with EGF (R&D). Samples of cell lysates (25 µg total protein) were analysed by western blotting with antibodies against phospho-EGFR, phospho-ERK, phospho-AKT and ERK (cat. nos 2220, 9101, 9271 and 9102, Cell Signaling Technology) and EGFR and AKT (sc-03 and sc-1618, Santa Cruz Biotechnology).

Targeted cDNA sequencing
------------------------

Sequences coding for *EGFR* kinase domain and *KRAS,* *NRAS,* *HRAS* or *BRAF* genes were PCR-amplified and purified using NucleoSpin Gel and PCR Clean-up kit (Macheney-Nagel). Both strands of amplified fragments were Sanger-sequenced for recurrent mutations (kinase domain for *EGFR*, codons 12, 13 and 61 for *RAS* genes, codon 600 for *BRAF*). Primers used in cDNA sequencing are described in Table S2 (see supplementary material).

BRAF V600E immunohistochemistry
-------------------------------

Immunohistochemical staining was performed using BRAF V600E mutation-specific antibody VE1 (Spring Biosciences), as previously described [@b9].

Statistical analyses
--------------------

Real-time RT--PCR data were analysed by one-way ANOVA, using the Games--Howell *post hoc* test. MTT cell viability assays were analysed by *t*-test. To analyse the relationships between *BRAF* mutation status and clinical patient data, Fisher\'s exact test was used. Association of *BRAF* mutation status with *EGFR* expression (high or low; above or below median expression, respectively) was analysed using Fisher\'s exact test. Statistical analyses were carried out using SPSS statistics v 20 (IBM).

Results
=======

*EGFR* and *ERBB4* are over-expressed in ameloblastoma
------------------------------------------------------

A real-time RT--PCR analysis of 23 solid/multicystic ameloblastomas (patient samples 1--23; Table [1](#tbl1){ref-type="table"}) was performed to study the expression of *ERBB* receptors. Eight KCOTs and six normal oral mucosa samples were included in the analysis as controls (see supplementary material, Table S1). *EGFR* and *ERBB4* were specifically over-expressed in ameloblastoma when compared to normal samples (*EGFR*, *p =* 0.003; *ERBB4*, *p* = 0.01) or to KCOT (*EGFR*, *p =* 0.001; *ERBB4*, *p \<* 0.001) (Figure [1](#fig01){ref-type="fig"}A, D). *EGFR* over-expression is in accordance with previous studies reporting high EGFR protein levels in ameloblastoma [@b4]--[@b6]. The predominantly expressed ERBB4 receptor isoforms in ameloblastoma were the JM-a isoforms (see supplementary material, Figure S1). For *ERBB2,* no statistically significant differences were observed (Figure [1](#fig01){ref-type="fig"}B). *ERBB3* was significantly more highly expressed in KCOT than in ameloblastoma (*p =* 0.011) (Figure [1](#fig01){ref-type="fig"}C).

![Real-time RT--PCR analysis of *ERBB* receptor expression in ameloblastoma, keratocystic odontogenic tumour (KCOT) and normal oral mucosa. Twenty-three ameloblastomas, eight KCOTs and six normal samples were analysed for *EGFR* (A), *ERBB2* (B), *ERBB3* (C) or *ERBB4* (D) expression.](path0232-0492-f1){#fig01}

Establishment of ameloblastoma cell lines
-----------------------------------------

To address the function of ERBB receptors in ameloblastoma, two non-immortalized primary ameloblastoma cell lines, AB10 and ABSV, were established from patient samples 3 and 12, respectively (Table [1](#tbl1){ref-type="table"}). A primary fibroblast cell line (ameloblastoma fibroblasts, AFs) was also established (from a tumour not analysed in this study). AB10 and ABSV cells were morphologically identical and formed an epithelial-like monolayer very similar to those of two previously published ameloblastoma cell lines [@b10],[@b11], whereas ameloblastoma fibroblasts demonstrated a typical spindle-shaped fibroblastic morphology (Figure [2](#fig02){ref-type="fig"}A). The ameloblastoma cells expressed high levels of epithelial markers *KRT14* (keratin 14), *KRT19* (keratin 19) and *CDH1* (E-cadherin) (Figure [2](#fig02){ref-type="fig"}B), whereas the expression of mesenchymal markers *CDH2* (N-cadherin) and *VIM* (vimentin) was almost undetectable (Figure [2](#fig02){ref-type="fig"}B). The *ERBB* receptor expression pattern was similar in both ameloblastoma cell lines (Figure [2](#fig02){ref-type="fig"}D) and corresponded to that observed in the ameloblastoma tumour samples (Figure [1](#fig01){ref-type="fig"}). However, neither of the cell lines expressed detectable levels of *ERBB4,* although *ERBB4* was expressed in the original tumour from which the AB10 cell line was established. This suggests that *ERBB4* expression was lost during cell line establishment.

![Characterization of established primary ameloblastoma tumour cell lines. (A) Established AB10, ABSV and ameloblastoma fibroblast cultures were grown on six-well plates and photographed using ×200 magnification. (B) The cell lines were analysed for the expression of epithelial markers *KRT14* (keratin 14), *KRT19* (keratin 19) and *CDH1* (E-cadherin) and mesenchymal markers *CDH2* (N-cadherin) and VIM (vimentin), using real-time RT--PCR. (C) AB10 and ABSV cell lines were analysed for *EGFR*, *ERBB2*, *ERBB3* and *ERBB4* expression, using real-time RT--PCR.](path0232-0492-f2){#fig02}

EGFR inhibition in ameloblastoma cells
--------------------------------------

The effect of EGFR inhibition on the proliferation of primary ameloblastoma cells was analysed by MTT cell viability assays. In AB10 cells, 72 h of treatment with the EGFR antibodies cetuximab and panitumumab already promoted a significant, dose-dependent reduction in proliferation at a concentration of 0.1 µg/ml (*p \<* 0.001) (Figure [3](#fig03){ref-type="fig"}A). Consistently, the EGFR tyrosine kinase inhibitors (TKI) erlotinib, gefitinib and AG1478 already significantly suppressed AB10 cell growth at the concentration of 0.01 μ[m]{.smallcaps} (*p \<* 0.001, *p =* 0.004, and *p \<* 0.001, respectively). However, similar treatment with the ERBB2-antibody trastuzumab did not demonstrate a dose-dependent effect (Figure [3](#fig03){ref-type="fig"}A). Treating AB10 cells with EGFR-targeted antibodies or TKIs abolished EGFR phosphorylation and silenced the RAS--RAF--MAPK and PI3K--AKT signalling pathways downstream of EGFR, as seen by a reduction of ERK and AKT phosphorylation after treatment (Figure [3](#fig03){ref-type="fig"}B). Consistent with the proliferation assays, ERBB2 inhibition had no major effect on the phosphorylation of ERK or AKT. When tested on the ABSV cells, however, neither panitumumab nor cetuximab had a significant effect on proliferation (Figure [3](#fig03){ref-type="fig"}A). The EGFR TKIs reduced proliferation of ABSV cells by 50%, but the effect was achieved only with the highest concentration of 10 μ[m]{.smallcaps}. Indeed, there was a clear, statistically significant difference in the sensitivity of AB10 and ABSV cells lines to EGFR inhibition (Figure [3](#fig03){ref-type="fig"}A).

![Effect of EGFR inhibition on ameloblastoma cells. (A) AB10 and ABSV cells were plated on 96-well plates and incubated for 72 h, with or without the indicated concentrations of EGFR monoclonal antibodies cetuximab or panitumumab, ERBB2 monoclonal antibody trastuzumab or EGFR tyrosine kinase inhibitors erlotinib, gefitinib or AG1478. Cell viability after incubation was estimated using the MTT assay. \*Significant differences between the proliferation of AB10 and ABSV cells (\**p \<* 0.05, \*\**p \<* 0.01, \*\*\**p \<* 0.001; Student\'s *t*-test). (B) AB10 cells were grown on six-well plates and treated overnight with cetuximab (10 µg/ml), panitumumab (10 µg/ml), trastuzumab (10 µg/ml), erlotinib (10 μ[m]{.smallcaps}), AG1478 (10 μ[m]{.smallcaps}), PI3-K inhibitor LY294002 (10 μ[m]{.smallcaps}) or MEK inhibitor PD98059 (10 μ[m]{.smallcaps}) or for 10 min with EGF (50 ng/µl). After treatment, phosphorylation of EGFR, AKT and ERK was analysed by western blotting, using phospho-specific antibodies (n.s., non-specific band). Total EGFR, AKT and ERK levels were determined using anti-EGFR, anti-AKT and anti-ERK antibodies. (C) The coding region of the *BRAF* gene was PCR-amplified from AB10 and ABSV cell cDNA, followed by Sanger sequencing of both strands of a 320 bp amplicon flanking the V600 codon of *BRAF*. The arrow indicates the mutated nucleotide responsible for the V600E substitution.](path0232-0492-f3){#fig03}

*BRAF* mutation is associated with resistance to EGFR-targeted drugs in primary ameloblastoma cells
---------------------------------------------------------------------------------------------------

Specific genetic markers predict the response to EGFR-targeted cancer drugs in the clinic and *in vitro* [@b12]--[@b20]. To test whether the differences observed in the responses to EGFR-targeted drugs in ameloblastoma cells were due to genetic factors, cDNA sequencing was performed to reveal mutations in the *EGFR* kinase domain or in the RAS--RAF--MAPK signalling pathway genes *KRAS,* *NRAS,* *HRAS* and *BRAF*. No mutations were observed in the *EGFR* kinase domain or in the *RAS* genes in either of the two cell lines. However, the unresponsive ABSV cell line harboured a BRAF V600E mutation (Figure [3](#fig03){ref-type="fig"}C), caused by a point mutation 1799T \> A. These findings demonstrate that the resistance of the ABSV cell line to EGFR-targeted drugs was associated with an activating mutation in a downstream signalling pathway.

*BRAF* mutations are frequent in ameloblastoma
----------------------------------------------

Twenty-four ameloblastoma samples were analysed for *BRAF* mutations by cDNA sequencing. BRAF V600E-specific immunohistochemistry was also performed for cases where appropriate tumour sections were available. Of 24 tumours, 15 (63%) were observed to harbour the BRAF V600E (1799T \> A) mutation (Figure [4](#fig04){ref-type="fig"}, Table [1](#tbl1){ref-type="table"}). In most cases, as in the ABSV cell line (Figure [3](#fig03){ref-type="fig"}C), the mutation appeared heterozygous (Figure [4](#fig04){ref-type="fig"}A). However, as the sequencing was performed from cDNA and the involvement of normal tissue could not be totally excluded, gene-level zygosity of the mutation could not be comprehensively addressed in the tumour samples. The mutations were found in patients with different ethnicities, including individuals of Caucasian (*n =* 6), Black-African (*n =* 7), Afro-Caribbean (*n =* 1) and Asian (*n =* 1) origin, with no significant association to specific ethnicity. *BRAF* mutation status also did not correlate with the sex or age of the patients, tumour histology, tumour recurrence or *EGFR* expression level (*p* \> 0.1). As expected, the original tumour from which the AB10 cell line was established (patient sample 3; Table [1](#tbl1){ref-type="table"}) was negative for the mutation and the tumour from which the ABSV line was established (patient sample 12; Table [1](#tbl1){ref-type="table"}) was positive. These findings suggest the presence of a high-frequency oncogenic mutation in clinical ameloblastoma.

![Analysis of BRAF V600E mutations in ameloblastoma tumour samples. (A) The coding region of the *BRAF* gene was PCR-amplified from tumour cDNA, followed by Sanger sequencing of both strands of a 320 bp region flanking the V600 codon of *BRAF*; arrow indicates the mutated nucleotide responsible for the V600E substitution. (B) Immunohistochemistry was performed for tumour sections using BRAF V600E-specific monoclonal antibody. Matching electropherograms and images from BRAF V600E immunohistochemistry are shown for BRAF V600E-positive (top, patient sample 20) and negative (bottom, patient sample 24) tumours.](path0232-0492-f4){#fig04}

Discussion
==========

The pathogenesis of ameloblastoma has remained elusive, despite considerable efforts to characterize the underlying molecular mechanisms. Here, the ERBB signalling in ameloblastoma was studied using clinical ameloblastoma samples as well as novel ameloblastoma cell lines. Real-time RT--PCR analysis of *ERBB* expression demonstrated a statistically significant over-expression of *EGFR* and *ERBB4* in ameloblastomas (*n =* 23) when compared to clinical samples of KCOT (*n =* 8) or to normal mucosa (*n =* 6). Pharmacological inhibition of EGFR suppressed the proliferation of one primary ameloblastoma cell line (AB10) but was ineffective for the other (ABSV). In the quest for factors underlying this difference, a BRAF V600E mutation was found in the resistant ABSV cell line. These observations demonstrate that, similar to *KRAS* mutations in colorectal cancer [@b12],[@b17],[@b18],[@b20], the BRAF V600E mutation is associated with resistance to EGFR-targeted drugs in ameloblastoma cells. BRAF V600E mutations were found in 63% (15 of 24) of the ameloblastoma samples. The high incidence of *BRAF* mutations represents the first indication of a high-frequency oncogenic mutation in ameloblastoma. Given the high response rate of BRAF V600E-positive metastatic melanoma to mutant BRAF-targeted inhibition by vemurafenib [@b21] or dabrafenib [@b22], our observations also offer a rationale for future testing of BRAF-targeted therapeutics for ameloblastoma.

The presence of activating *BRAF* mutations suggests the involvement of a hyperactive RAS--RAF--MAPK pathway in the pathogenesis of ameloblastomas. The observed dependency of AB10 cells on EGFR signalling supports this hypothesis, as the RAS--RAF--MAPK pathway is well known to operate downstream of [@b23], and as ERK phosphorylation was completely abolished in response to EGFR inhibition in these cells. Interestingly, transgenic mice carrying the *vHa-RAS* oncogene, a constitutively active homologue of the human *HRAS,* develop odontogenic tumours that closely resemble human ameloblastoma [@b24],[@b25].

Taken together, our results indicate that a hyperactive RAS--RAF--MAPK pathway is closely associated with ameloblastoma pathogenesis, either through EGFR-mediated signalling or through frequent activating mutations in the *BRAF* gene. Thus, our observations offer for the first time a rationale for designing targeted therapies in ameloblastoma.
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